Correlations of objective metrics for quantifying dysfunctional lens syndrome with visual acuity and phacodynamics
Session Details
Session Title: Quality of Vision and Dry Eye
Session Date/Time: Sunday 08/10/2017 | 08:00-09:30
Paper Time: 08:42
Venue: Room 3.4
First Author: : F.Faria-Correia PORTUGAL
Co Author(s): : I. Ramos B. Lopes N. Franqueira T. Monteiro R. Ambrosio Jr.
Abstract Details
Purpose:
To study the relationship between objective metrics for quantifying crystalline lens dysfunction with visual impairment and phacodynamics parameters in age-related nuclear cataracts.
Setting:
Hospital de Braga; Instituto CUF; Hospital CUF Porto
Methods:
Fifty-one eyes (34 patients) with age-related nuclear cataract were submitted to phacoemulsification. The DLI (0 to 10 points) was measured by a ray-tracing aberrometry (iTrace Visual Function Analyzer, Tracey Technologies, Houston, Texas). The average lens density (0 to 100) was evaluated by using a rotating Scheimpflug system (Pentacam HR, Oculus, Wetzlar, Germany) and the nuclear opalescence (NO) score was subjectively assessed using the Lens Opacities Classification System III (LOCS III). The different parameters for evaluating crystalline lens dysfunction were correlated with preoperative corrected distance visual acuity (CDVA) and cumulative dissipated energy (CDE).
Results:
There was a negative linear correlation between the DLI and the LOCS III NO and Scheimpflug-measured average density (r =-0.728 and r = -0.771, respectively; both P<.01). The preoperative CDVA was correlated with the Scheimpflug-measured lens nuclear density value (r = 0.612, P <.01) and DLI score A (r =-0.670, P <.01). The CDE was more strongly correlated with DLI and Scheimpflug-derived average density (r =-0.744 and r = 0.700, respectively; both P<.01) than with LOCS III NO (r = 0.646, P<.01).
Conclusions:
The DLI was correlated with the Scheimpflug-measured average density, subjective lens grading and preoperative CDVA. This metric also presented the highest correlation with phacodynamics. Correlation with other clinical measures related to visual quality and impairment are still needed.
Financial Disclosure:
receives nonNONEmonetary benefits from a company producing, developing or supplying the product or procedure presented.